^
Association details:
| Biomarker: | BRCA1 mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
01/25/2024
Excerpt:
HR-Negative and HER2-Negative (Triple-Negative Breast Cancer...Germline BRCA1/2 mutation...PARPi (olaparib, talazoparib) (Category 1, preferred)
Source:
Published date:
12/10/2021
Excerpt:
Recommendation 1.4...Patients with metastatic triple-negative breast cancer with germline BRCA1 or 2 mutations who have previously been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic disease setting may be offered an oral poly (ADP-ribose) polymerase (PARP) inhibitor (olaparib or talazoparib) rather than chemotherapy...
DOI:
10.1200/JCO.21.01374
Source:
Title:
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Published date:
07/19/2018
Excerpt:
A PARPi (olaparib or talazaparib) is a reasonable treatment option for patients with BRCA-associated advanced TNBC or luminal (after progression on ET) ABC, previously treated with an anthracycline with/without a taxane (in the adjuvant and/or metastatic setting), since its use is associated with a PFS benefit, improvement in QoL and a favourable toxicity profile.
DOI:
10.1093/annonc/mdy192
Source:
Title:
Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).
Published date:
05/16/2018
Excerpt:
Of 431 pts randomized, 241 had HR+ BC and 190 had TNBC. ORR for TALA was similar for the 2 groups: 61.8% for TNBC vs 63.2% for HR+. Duration of response median for TALA was longer for HR+ (6.8 months) compared to TNBC (4.3 months); both groups included a subset with a prolonged response to TALA...Talazoparib demonstrated improved PFS and ORR in pts both with gBRCAmut HR+ BC and TNBC.
DOI:
10.1200/JCO.2018.36.15_suppl.1070
Trial ID:
Title:
Regulator OKs Pfizer's BRCA mutation breast cancer treatment
Excerpt:
Pfizer Korea said that the Ministry of Food and Drug Safety has approved Talzenna, its BRCA (Breast Cancer Susceptibility Gene) mutation breast cancer targeted therapy....treatment as monotherapy for germline BRCA (gBRCA) mutations and HER2 (human epithelial cell growth factor receptor 2) negative locally advanced or metastatic breast cancer patients have previously had chemotherapy.
Source:
Title:
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Excerpt:
...- Patients with only a VUS (Variant of Unknown Significance), or non-functional BRCA mutation, without a deleterious somatic BRCA 1 or 2 mutation will...
Trial ID:
Source:
Title:
Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature
Excerpt:
......
Trial ID:
More C2 evidence
Source:
Title:
Talazoparib Maintenance Therapy in Triple-negative Breast Cancer
Excerpt:
...Patients who can receive germline BRCA1/2 mutation test or patients with previously known germline BRCA1/2 mutation status....
Trial ID:
Less C2 evidence
Source:
Title:
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
Published date:
06/15/2023
Excerpt:
Patients with germline BRCA1/2-mutated early-stage TNBC received talazoparib 1 mg once daily for 24 weeks (0.75 mg for moderate renal impairment) followed by surgery….pCR rate was 45.8% (95% confidence interval [CI], 32.0%-60.6%) and 49.2% (95% CI, 36.7%-61.6%) in the evaluable and intent-to-treat (ITT) population, respectively....
DOI:
10.1093/oncolo/oyad139
Trial ID:
